The present study was undertaken to assess the efficacy of gemfibrozil [2,2-dimethyl-5-(2,5xylyloxy)-valeric acid] in lowering total serum cholesterol and triglyceride levels when these are initially high, and to determine the effect of gemfibrozil on the cholesterol and triglyceride content of different lipoprotein fractions. We have also studied the effect of gemfibrozil on serum insulin concentrations before and after an intravenous glucose load, on glucose tolerance and on lipoprotein lipase activity in adipose tissue. It was shown that gemfibrozil is an effective lipid lowering compound and an interesting alternative to presently available lipid lowering drugs. No adverse effects attributable to gemfibrozil were recorded during the trial.
MATERIALS AND METHODS

Patients
Thirty adult outpatients with primary hyperlipoproteinemia according to the criteria of Fredrickson et al. (1967) and Beaumont et al. (1970) were selected. Twenty-four patients were male and 6 were female. Their ages ranged from 39 to 69 years (mean 50.3 years). Subjects who had received other lipid lowering drugs were only included in the trial after an interval of six weeks following discontinuation of the previous drug. All patients were on dietary treatment for at least six weeks before the trial in order to obtain weight stabilization and firm base line values for serum lipids. No patients with secondary hyperlipoproteinmmia caused by the nephrotic syndrome, myxcedema, diabetes mellitus or liver disease, or on medication known to affect serum lipid levels, were included.
Design and Dosage
This was a single-blind placebo-controlled trial using a fixed dose schedule. The change-over was undertaken after six weeks. Eleven patients received gemfibrozil during the first six-week period, while the remaining 19 patients started with placebo. The 12-week treatment was followed by a four-week wash-out period. Diet and concurrent medication were kept unchanged during the entire trial.
Gemfibrozil (200 mg capsules) and placebo (lactose) were dispensed in identical capsules and Dr B Vessby patients were given two capsules three times daily. Thus all patients received 1200 mg of gemfibrozil daily for six weeks. The patients were seen twice during the placebo period and at the end of each two-week period during gemfibrozil therapy. At each visit the patients were weighed and any adverse effects were recorded. At the final visit of each six-week period the patients were examined clinically and a capsule count was undertaken.
Laboratory Methods
Heematology (hemoglobin concentration, hlematocrit, WBC and platelet count and ESR), liver function tests (SGOT, SGPT, LDH, alkaline phosphatase and bilirubin), serum creatinine and urine analyses were monitored at every visit throughout the trial in the interests of safety. Serum lipid concentrations (see below) were determined at each visit. Quantitative determinations of serum lipoprotein lipid concentrations were performed at the beginning of the trial and after the placebo and gemfibrozil treatment periods. An intravenous glucose tolerance test (Ikkos & Luft 1957) with determinations of serum insulin concentrations (Velasco et al. 1974 ) before and after the glucose load, assay of lipoprotein lipase activity in adipose tissue (see below) and determination of plasma fibrinogen concentrations (Lizana & Hellsing 1974) were also performed after both the placebo and gemfibrozil treatments.
Lipoprotein lipid concentrations were determined in serum after a 12-14 h overnight fast. EDTA was added to serum as a 5 % solution to a final concentration of 0.05 %. Very low density lipoproteins (VLDL) were isolated as the top fraction at d= 1.006 after centrifugation for 16 h at 15°C at 105 000 g in a Beckman L2-65B preparative ultracentrifuge using a 40.3 rotor (Havel .'t al. 1955) . The low density lipoproteins (LDL) were precipitated from the bottom fraction at d = 1.006 by a heparin-manganese chloride solution. After low speed centrifugation the high density lipoprotein (HDL) lipid levels were determined in the supernatant (Burstein & Samaille 1960) . The concentrations of lipids in LDL were obtained indirectly by subtracting the HDL lipid levels from the lipid concentrations in the bottom fraction after centrifugation at d = 1.006.
Cholesterol and triglyceride concentrations of serum and of the isolated lipoprotein classes were determined in isopropanol extracts by semiautomatic methods in a Technicon Auto Analyzer type II (Rush et al. 1971) . The recovery of triglycerides and cholesterol in the isolated density classes was in all samples within 10010%. The top and bottom fraction at d= 1.006 as well as whole serum were analysed with agarose electrophoresis (Noble 1968 ).
Lipoprotein lipase activity in adipose tissue was determined by measuring the release of 14Clabelled fatty acids from a serum activated soybean oil-phospholipid emulsion in a reaction medium containing heparin, albumin and a glycine-NaOH buffer (Lithell et al. 1976 ).
Statistics
The data presented are, if not otherwise stated, based on individual comparisons between results recorded after the gemfibrozil and placebo 
RESULTS
Dose per Day
A count of the number of capsules returned showed that the patients on average had consumed 1.03+0.04 g/day (mean +s.e.). Three patients had on average taken less than 800 mg of gemfibrozil per day, i.e. less than 67% of the prescribed dose. If these 3 subjects were excluded, the average dose of gemfibrozil was 1.09±0.02 g/day.
Body Weight
The weight changes from period to period during placebo and gemfibrozil treatment were within +2 kg in 24 patients. Six patients showed weight changes up to 3.3 kg. The average body weight during placebo and gemfibrozil treatment did not differ significantly (78.1 ±1.4 kg compared to 78.0± 1.3 kg).
Classification ofthe Lipoprotein Patterns
The classification of the lipoprotein patterns made on samples drawn immediately after the placebo period will in some cases differ from a classification made on pretreatment samples. The limits for 'normolipidimia' for men and women respectively were: for VLDL triglycerides 1.40 and 1.00 mmol/l and for LDL cholesterol 200 and 220 mg/100 ml. Two patients with hyperlipidcemia before the trial had a 'normal' lipoprotein pattern after the placebo period, although the serum lipid concentrations fell within the upper 'normal' range (Table 1) . After gemfibrozil treatment 53 % (16 of 30) of the patients showed a normal lipoprotein pattern.
Effects ofGemfibrozil on Serum Lipoprotein Lipid Concentrations
The mean serum lipoprotein lipid concentrations of all 30 patients during treatment with placebo and gemfibrozil are shown in Table 2 . A highly (Fig 1) . Over 90 % of the total serum triglyc tion during gemfibrozil treatment during the first three weeks of the six ment period. The mean serum trigl) centration at six weeks was not . different from the three-week value. C hand, more than one-third of the I cholesterol reduction took place duri three weeks of treatment, and the esterol concentration at six weeks was i lower than that at three weeks (P<0.0
When recorded at four weeks after treatment, the mean serum trigly cholesterol concentrations were still re pared to the corresponding values t fibrozil therapy. The difference with regard to serum triglycerides was not statistically significant (P<0.1) but the serum cholesterol was signifi- (Table 3 ). The majority (10 of 12) of the patients were classified triglycerides as type Ilb. These patients also showed a dramatic 9% was re-reduction of VLDL triglyceride and cholesterol ibrozil. The concentrations by over 60%, and a serum tri-)ncentration glyceride reduction by about 50%. Only 2 type concentra-Ila patients were included in this trial. They at the major showed a mean serum cholesterol reduction of cholesterol 33 %, and an LDL cholesterol reduction of 39 %. DL but in-Lnge in LDL Effects of Gemfibrozil Treatment on Serum atment was Lipoprotein Concentrations in Patients with esterol con-Hypertriglycerida?mia Table 4 shows the effects of gemfibrozil on lipo--eride reducprotein lipid concentration in patients with hypertook place triglyceridemia without a concomitantly in--week treat-creased LDL cholesterol concentration (14 type yceride con-IV, 2 type III). The mean percentage reduction of significantly VLDL triglyceride and cholesterol concentrations )n the other was 45 %, corresponding to a serum triglyceride total serum reduction of 40%. The reduction of serum ing the final cholesterol was solely due to reduced VLDL mean cholcholesterol levels, while the mean LDL and HDL significantly cholesterol concentrations did not change sig-1).
nificantly. cessation of
The seemingly less pronounced reduction of rceride and VLDL lipid levels in patients with hyperlipoproduced com-teinemia type IV (Table 4 ) compared to that in before gem-patients with type Ilb (Table 3) the fact that the former group contained the 3 patients who had consumed less than 800 mg of gemfibrozil daily, as well as 1 patient with high lipid levels and known alcohol abuse during the treatment period. If these 4 patients were excluded, the mean reduction in the 10 remaining type IV patients for VLDL triglycerides and cholesterol was about 60%. The serum triglyceride concentration was reduced by 50 % and the HDL cholesterol concentration increased by 8 % (P<0.05).
Criteria ofEffect
The criteria of effect before the trial were defined as:
(1) Reduction of increased serum triglyceride levels by 35% or more of the level during the placebo period or to within normal limits.
(2) Reduction of increased serum cholesterol levels by 15 % or more or to within normal limits.
The 4 patients mentioned above were excluded because of low daily intake of gemfibrozil (3) and alcohol overconsumption (i). Twenty-one of the remaining patients showed increased serum triglycerides, and 14 showed increased serum cholesterol at the end of the placebo period. Only 1 of the 21 patients with hypertriglyceridmmia and 1 of the 14 patients with hypercholesterolkmia did not fulfil the criteria of effects as defined above.
Effects ofGemfibrozil on Glucose Tolerance, Serum Insulin Concentrations, Lipoprotein Lipase Activity in Adipose Tissue and Plasma Fibrinogen Levels There was no significant change in the mean fasting blood glucose concentrations or in glucose tolerance during gemfibrozil treatment (Table 5 ). The serum insulin concentrations before and after intravenous glucose injection remained unchanged (Fig 2) . The adipose tissue lipoprotein lipase activity and the plasma fibrinogen levels were not affected by gemfibrozil (Table 5) .
Adverse Effects ofGemfibrozil Treatment
The results of the laboratory studies performed in the interests of safety are shown in Table 6 . Except for a tendency to reduced haematocrit values, there was no significant effect on the hxematological variables studied. As for the liver function tests, there was a clinically insignificant, but statistically highly significant reduction of the serum bilirubin levels during gemfibrozil treatment. Serum creatinine concentrations remained stable. No adverse urinary findings were recorded. No adverse reactions attributable to the trial drug were reported by the patients.
DISCUSSION
The present study indicates that gemfibrozil administered in a dose of 1200 mg daily during medium-term treatment is an effective lipid lowering compound capable of reducing increased serum triglyceride levels by approximately 50% and increased serum cholesterol concentration by about 20%. Elevated VLDL triglyceride levels were reduced by 60 %, and increased LDL cholesterol concentrations by approximately 20 %. The direct relationship between pretreatment LDL cholesterol concentrations and the reduction of LDL cholesterol achieved during treatment insulin conc. ,MU/mt 50 (Fig 1) has earlier been reported during other hypolipidemic regimens (CarIson et al. 1974 ). The increased HDL cholesterol concentrations recorded in response to treatment with gemfibrozil should probably be considered a beneficial effect (Miller & Miller 1975) . No adverse reactions attributable to gemfibrozil were recorded during this trial.
It thus seems as if gemfibrozil, as well as clofibrate, has a more pronounced effect on serum triglycerides than on serum cholesterol. The average serum lipid reductions recorded during treatment with gemfibrozil at 1200 mg daily seem to be readily comparable to those achieved with clofibrate given at 2 g daily (for a recent review see Gustafson 1975) . Whether a maximum lipid lowering effect is achieved with 1200 mg of gemfibrozil or whether a dose-response effect may be seen by further increasing the dose has to be established in subsequent trials. It is also possible that a somewhat more pronounced lipid lowering effect may be achieved in prolonged studies, as the present data indicate that a relatively long treatment period is needed to achieve a maximum effect on the serum cholesterol levels.
In comparable studies, clofibrate in a dose of 2 g daily has shown reduced fasting serum insulin concentrations, reduced serum alkaline phosphatase activity and reduced plasma fibrinogen levels and ESR (Lithell et al. 1976 ). None of these effects was seen in this trial during treatment with gemfibrozil. This may indicate that the mechanisms behind the lipid lowering effects achieved with the two drugs are at least partly different. A tendency to impaired glucose tolerance and increased fasting blood glucose and serum insulin concentrations has been reported during prolonged treatment with nicotinic acid, for example, by Marks et al. (1971) . No such effects were seen during treatment with gemfibrozil.
In the present study, gemfibrozil has proved to be an efficient lipid lowering agent, which seems to have few adverse effects. In the search for alternatives to presently available lipid lowering drugs, gemfibrozil is no doubt a compound of interest.
SUMMARY
The efficacy of gemfibrozil in lowering increased serum lipoprotein concentrations was tested in a placebo-controlled cross-over trial on 30 patients. Administered in a dose of 1200 mg daily, gemfibrozil reduced increased serum triglyceride levels by approximately 50 % and reduced increased serum cholesterol concentrations by about 20%. Elevated VLDL triglyceride levels were reduced by 60 %, and increased LDL cholesterol concentrations were reduced by approximately 20%. The mean HDL cholesterol concentration increased during gemfibrozil treatment. No adverse reactions attributable to gemfibrozil were recorded during the trial.
